487 related articles for article (PubMed ID: 29474847)
21. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma.
Seelemeyer F; Pfister D; Pappesch R; Merkelbach-Bruse S; Paffenholz P; Heidenreich A
Eur Urol Oncol; 2024 Jun; 7(3):319-322. PubMed ID: 37932157
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
[TBL] [Abstract][Full Text] [Related]
23. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF
World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209
[TBL] [Abstract][Full Text] [Related]
24. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.
Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ
Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479
[TBL] [Abstract][Full Text] [Related]
25. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
27. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.
Wood DP; Herr HW; Heller G; Vlamis V; Sogani PC; Motzer RJ; Fair WR; Bosl GJ
J Urol; 1992 Dec; 148(6):1812-5; discussion 1815-6. PubMed ID: 1331547
[TBL] [Abstract][Full Text] [Related]
28. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?
Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R
Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259
[TBL] [Abstract][Full Text] [Related]
29. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.
Baessler B; Nestler T; Pinto Dos Santos D; Paffenholz P; Zeuch V; Pfister D; Maintz D; Heidenreich A
Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413
[TBL] [Abstract][Full Text] [Related]
30. MicroRNAs in Testicular Germ Cell Tumors: The Teratoma Challenge.
Yodkhunnatham N; Pandit K; Puri D; Yuen KL; Bagrodia A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396829
[TBL] [Abstract][Full Text] [Related]
31. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.
Dieckmann KP; Spiekermann M; Balks T; Ikogho R; Anheuser P; Wosniok W; Loening T; Bullerdiek J; Belge G
Urol Int; 2016; 97(1):76-83. PubMed ID: 26989896
[TBL] [Abstract][Full Text] [Related]
33. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.
Logothetis CJ; Swanson DA; Dexeus F; Chong C; Ogden S; Ayala AG; von Eschenbach AC; Johnson DE; Samuels ML
J Clin Oncol; 1987 Jun; 5(6):906-11. PubMed ID: 2438389
[TBL] [Abstract][Full Text] [Related]
34. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
Besse B; Grunenwald D; Fléchon A; Caty A; Chevreau C; Culine S; Théodore C; Fizazi K
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):448-52. PubMed ID: 19185168
[TBL] [Abstract][Full Text] [Related]
35. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.
Paffenholz P; Nestler T; Hoier S; Pfister D; Hellmich M; Heidenreich A
Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832
[TBL] [Abstract][Full Text] [Related]
36. A Machine Learning Model to Predict the Histology of Retroperitoneal Lymph Node Dissection Specimens.
Nitta S; Kojima T; Gido M; Nakagawa S; Kakeya H; Kandori S; Kawahara T; Mathis BJ; Kawai K; Negoro H; Nishiyama H
Anticancer Res; 2024 May; 44(5):2151-2157. PubMed ID: 38677742
[TBL] [Abstract][Full Text] [Related]
37. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
Speir RW; Calaway AC; Einhorn LH; Foster RS; Cary C
Urol Oncol; 2020 Aug; 38(8):687.e19-687.e23. PubMed ID: 32448503
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
39. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
Herr HW; Toner GC; Geller NL; Bosl GJ
Eur Urol; 1991; 19(1):1-5. PubMed ID: 1848821
[TBL] [Abstract][Full Text] [Related]
40. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
